This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, P. J. Articles by Jaffe, E. S. Search for Related Content PubMed PubMed Citation Articles by Cohen, P. J. Articles by Jaffe, E. S.

American Journal of Pathology, Vol 129, 208-216, Copyright © 1987 by American Society for Investigative Pathology

REGULAR ARTICLES

The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression

PJ Cohen, MT Lotze, JR Roberts, SA Rosenberg and ES Jaffe
Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892.

Sequential tumor biopsies from 9 patients with disseminated cancers were obtained before, during, and after treatment with interleukin-2 (IL-2) with or without the adoptive transfer of lymphokine-activated killer (LAK) cells. Infiltrating lymphoid and tumor cells were characterized in frozen sections by the use of monoclonal antibodies and the avidin-biotin complex (ABC) immunoperoxidase technique. Five patients had objective tumor regression (1 complete response of a follicular lymphoma, 4 partial responses of melanomas). Four patients (2 melanomas, 1 renal cell carcinoma, 1 breast carcinoma) were nonresponsive after treatment. After treatment, responsive tumors showed a pronounced infiltration of T cells, mainly Leu-2+ (CD8, primarily cytotoxic/suppressor) cells. Macrophages, although increased, were fewer than the T cells, and Leu-7+ or Leu-11+ (NK and K) cells were virtually absent. In nonresponders, there was no significant increase in lymphoid cells after therapy, and no differences were noted between groups before therapy. In 4 of 5 responders, tumor cells were positive for HLA-DR before therapy; and in the remaining responder, the tumor became positive during treatment. Tumor cells in all biopsy specimens from nonresponders were DR- before and after the start of therapy. It is concluded that the expression of HLA-DR by tumor cells may play a role in the response to IL-2 with or without LAK and that marked infiltration by T cells accompanies, and possibly mediates, such a response.

This article has been cited by other articles:

				L. M. Rimsza, R. A. Roberts, T. P. Miller, J. M. Unger, M. LeBlanc, R. M. Braziel, D. D. Weisenberger, W. C. Chan, H. K. Muller-Hermelink, E. S. Jaffe, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project Blood, June 1, 2004; 103(11): 4251 - 4258. [Abstract] [Full Text] [PDF]

				J. Manne, M. J. Mastrangelo, T. Sato, and D. Berd TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine J. Immunol., September 15, 2002; 169(6): 3407 - 3412. [Abstract] [Full Text] [PDF]

				T. M. Carlos Leukocyte recruitment at sites of tumor: dissonant orchestration J. Leukoc. Biol., August 1, 2001; 70(2): 171 - 184. [Abstract] [Full Text] [PDF]

				M. Feinmesser, A. Sulkes, S. Morgenstern, J. Sulkes, S. Stern, and E. Okon HLA-DR and {beta}2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities J. Clin. Pathol., April 1, 2000; 53(4): 286 - 291. [Abstract] [Full Text] [PDF]

				M. Hishii, D. Andrews, L. A. Boyle, J. T. Wong, F. Pandolfi, P. J. van den Elsen, and J. T. Kurnick In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites PNAS, February 18, 1997; 94(4): 1378 - 1383. [Abstract] [Full Text] [PDF]